Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PPARγ mutations, lipodystrophy and diabetes.

Hormone molecular biology and clinical investigation - 1 Nov 2014

Astapova Olga, Leff Todd

Abstract excerpt

The focus of this review is the lipodystrophy syndrome caused by mutation in the PPARγ nuclear receptor - partial familial lipodystrophy FPLD3. To provide a broader context for how these mutations act to generate the clinical features of partial lipodystrophy we will review the basic biology of PPARγ and also survey the set PPARγ genetic variants that do not cause lipodystrophy, but are nonetheless associated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Diabetes Mellitus, Type 2
Share to Genetic Variation
Share to Lipodystrophy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to PPAR gamma

Source

Identifiers

PMID: 25460295
DOI: 10.1515/hmbci-2014-0033

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PPARγ mutations, lipodystrophy and diabetes.PMID 25460295Read ↗

Familial partial lipodystrophy resulting from loss-of-function PPARγ pathogenic variants: phenotypic, clinical, and genetic features.Semantic proximity Read ↗

Clinical and molecular characterization of a severe form of partial lipodystrophy expanding the phenotype of PPARγ deficiency.Semantic proximity Read ↗

The Novel Loss-of-function Arg212Trp Mutation in PPARG Causes Familial Partial Lipodystrophy Type 3Semantic proximity Read ↗

Genomic and Bioinformatics Analysis of Familial Partial Lipodystrophy Type 3 Identified in a Patient with Novel PPARγ Mutation and Robust Response to Pioglitazone.Semantic proximity Read ↗

A Pharmacogenetic Approach to the Treatment of Patients With PPARG MutationsSemantic proximity Read ↗

Familial partial lipodystrophy type 3: a new mutation on the PPARG gene.Semantic proximity Read ↗

Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistance.Semantic proximity Read ↗

A Novel PPARG R212W Variant Causes Familial Partial Lipodystrophy Type 3: Clinical Presentation and Functional Characterization.Semantic proximity Read ↗

New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligandSemantic proximity Read ↗

Peroxisome proliferator-activated receptor-γ mutations responsible for lipodystrophy with severe hypertension activate the cellular renin-angiotensin system.Semantic proximity Read ↗

PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy.Semantic proximity Read ↗

Case Report: A New Peroxisome Proliferator-Activated Receptor Gamma Mutation Causes Familial Partial Lipodystrophy Type 3 in a Chinese Patient.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.